Article
LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
Cancer letters - 28 Aug 2020
Chen Chen, Liu Wei-Ran, Zhang Bin, Zhang Lian-Min, Li Chen-Guang, Liu Chang, Zhang Hua, Huo Yan-Song, Ma Yu-Chen, Tian Peng-Fei, Qi Qi, Li Jing-Jing, Tang Zhe, Zhang Zhen-Fa, Giaccone Giuseppe, Yue Dong-Sheng, Wang Chang-Li
Abstract excerpt
First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib have significant activity in NSCLC patients with activating EGFR mutations. However, EGFR-TKI resistance inevitably occurs after approximately 12 months of treatment. Acquired mechanisms of resistance, other than secondary mutations in EGFR (T790 M) which account for 50-60%, are less well understood. Here, we identified lncRNA H19 as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.